References
- Mooradian AD, Morley JE, Korenman SG. Bio- logical actions of androgens. Endocr Rev 1987; 8:1–27
- Morales A, Lunenfeld B. Investigation, treatment and monitoring late-onset hypogonadism in males. Aging Male 2002;5:74–86
- Jockenhövel F. Männlicher Hypogonadismus –Aktuelle Aspekte der Androgensubstitution. Bremen: UniMed Verlag, 1999
- Jockenhövel F. Practical aspects of testosterone substitution. Aging Male 2002;5(Suppl 1):21–46
- Schürmeyer T, Wickings EJ, Freischem CW,Nieschlag E. Saliva and serum testosterone follow- ing oral testosterone undecanoate administration in normal and hypogonadal men. Acta Endocrinol 1983;102:456–62
- Gooren LJ. A ten-year safety study of the oral androgen testosterone undecanoate. J Androl 1994; 15:212–15
- Schürmeyer T, Nieschlag E. Comparative pharmacokinetics of testosterone enanthate and testosterone cyclohexanecarboxylate as assessed by serum and salivary testosterone levels in normal men. Int J Androl 1984;7:181–7
- Schulte-Beerbühl M, Nieschlag E. Comparison of testosterone, dihydrotestosterone, luteinizing hormone, and follicle-stimulating hormone in serum after injection of testosterone enanthate or testosterone cypionate. Fertil Steril 1980;33:201–3
- Nieschlag E, Cüppers HJ, Wiegelmann W, Wickings EJ. Bioavailability and LH-suppressing effect of different testosterone preparations in normal and hypogonadal men. Horm Res 1976; 7:138–45
- Jockenhövel F, Vogel E, Kreutzer M, Reinhardt W, Lederbogen S, Reinwein D. Pharmacokinetics and pharmacodynamics of subcutaneous testos- terone implants in hypogonadal men. Clin Endo- crinol 1996;45:61–71
- Jockenhövel F, Blum WF, Vogel E, Englaro P, Müller-Wieland D, Reinwein D, et al. Testoster- one substitution normalizes elevated leptin serum levels in hypogonadal men. J Clin Endocrinol Metab 1997;82:2510–13
- Jockenhövel F, Bullmann C, Schubert M, Vogel E, Reinhardt W, Reinwein D, et al. Influence of various modes of androgen substitution on serum lipids and lipoproteins in hypogonadal men. Metabolism 1999;48:590–6
- Jockenhövel F, Vogel E, Reinhardt W, Reinwein D. Effects of various modes of androgen substitu- tion therapy on erythropoiesis. Eur J Med Res 1997;2:293–8
- Schubert M, Bullmann C, Oettel M, Hübler D, Ernst M, Ezzidin S, et al. Intramuscular applica- tion of testosterone undecanoate – a novel mode of androgen substitution with sustained dura- tion. Exp Clin Endocrinol Diabetes 1999;107 (Suppl 1):S62
- Nieschlag E, Buchter D, von Eckardstein S, Abshagen K, Simoni M, Behre HM. Repeated intramuscular injections of testosterone unde- canoate for substitution therapy in hypogonadal men. Clin Endocrinol 1999;51:757–63
- Minnemann T, Christoph A, Hübler D, Oettel M, Krone W, Jockenhövel F. Long-term efficacy of intramuscular testosterone undecanoate in hypo- gonadal men. Proceedings of the 83rd Annual Meeting of the American Society of Endocrinology, 2001:Abstr P2–472
- Bals-Pratsch M, Knuth UA, Yoon Y-D, Nieschlag E. Transdermal testosterone substitution therapy for male hypogonadism. Lancet 1986;4:943–6
- Cunningham GR, Cordero E, Thornby JI. Testos- terone replacement with transdermal therapeutic systems. J Am Med Assoc 1989;261:2525–30
- Meikle AW, Arver S, Dobs AS, Sanders SW, Lakshminaryan R, Mazer NA. Pharmacokinetics and metabolism of a permeation-enhanced testos- terone transdermal system in hypogonadal men: influence of application site – a clinical research center study. J Clin Endocrinol Metab 1996; 81:1832–40
- Jordan WP. Allergy and topical irritation associated with transdermal testosterone administration: a comparison of scrotal and nonscrotal transdermal systems. Am J Cont Dermat 1997;8:108–13
- Parker S, Armitage M. Experience with trans-dermal testosterone replacement therapy for hypogonadal men. Clin Endocrinol 1999;50:57–62
- Wang C, Berman N, Longstreth JA, Chuapoco B, Hull L, Steiner B, et al. Pharmacokinetics of transdermal testosterone gel in hypogonadal men: application of gel at one site versus four sites: a general clinical research center study. J Clin Endo- crinol Metab 2000;85:964–9
- Swerdloff RS, Wang C, Cunningham GR, Dobs AS, Iranmanesh A, Matsumoto AM, et al. Long- term pharmacokinetics of transdermal testosterone gel in hypogonadal men. J Clin Endocrinol Metab 2000;85:4500–10
- Wang C, Swerdloff RS, Iranmanesh A, Dobs AS, Snyder PJ, Cunningham GR, et al. Transdermal testosterone gel improves sexual function, mood, muscle strength, and body composition parameters in hypogonadal men. J Clin Endocrinol Metab 2000; 85:2839–53